Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TEN
526
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $4.09M | ﹤0.01% |
70,509
-11,559
| -14% | -$668K |
|
527
Moog Inc Class A
MOG.A
$12.4B
| $3.99M | ﹤0.01% |
60,907
-260,856
| -81% | -$16.6M |
|
528
EQT Corp
EQT
$32.9B
| $3.94M | ﹤0.01% |
74,692
+63,663
| +577% | +$3.32M |
|
529
Johnson & Johnson
JNJ
$640B
| $3.84M | ﹤0.01% |
39,068
+6,003
| +18% | +$557K |
|
530
Brunswick
BC
$5.23B
| $3.83M | ﹤0.01% |
+84,679
| New | +$3.73M |
|
531
Norfolk Southern
NSC
$75.4B
| $3.82M | ﹤0.01% |
39,346
+2,534
| +7% | +$235K |
|
532
BioCryst Pharmaceuticals
BCRX
$2.42B
| $3.79M | ﹤0.01% |
358,557
+1,205
| +0.3% | +$12.8K |
|
533
Archer Daniels Midland
ADM
$38.7B
| $3.76M | ﹤0.01% |
86,588
+10,518
| +14% | +$434K |
|
534
Macy's
M
$6.51B
| $3.71M | ﹤0.01% |
62,501
-1,978
| -3% | -$110K |
|
535
IBM
IBM
$213B
| $3.68M | ﹤0.01% |
+19,996
| New | +$3.52M |
|
|
MGLN
536
DELISTED
Magellan Health Services, Inc.
MGLN
| $3.64M | ﹤0.01% |
61,388
-5,699
| -8% | -$339K |
|
|
GNCA
537
DELISTED
Genocea Biosciences, Inc.
GNCA
| $3.64M | ﹤0.01% |
+25,000
| New | +$3.06M |
|
538
DuPont de Nemours
DD
$18.6B
| $3.56M | ﹤0.01% |
28,974
-2,598
| -8% | -$306K |
|
|
AET
539
DELISTED
Aetna Inc
AET
| $3.55M | ﹤0.01% |
47,306
-893,602
| -95% | -$63.2M |
|
540
Amgen
AMGN
$209B
| $3.47M | ﹤0.01% |
28,159
-20
| -0.1% | -$2.43K |
|
541
Kroger
KR
$36.7B
| $3.46M | ﹤0.01% |
158,426
-2,691,038
| -94% | -$53.6M |
|
542
Danaher
DHR
$138B
| $3.45M | ﹤0.01% |
+68,381
| New | +$3.48M |
|
|
SDRL
543
DELISTED
Seadrill Limited Common Stock
SDRL
| $3.39M | ﹤0.01% |
360
+59
| +20% | +$580K |
|
544
Whirlpool
WHR
$2.49B
| $3.35M | ﹤0.01% |
22,428
+18,142
| +423% | +$2.63M |
|
545
Encompass Health
EHC
$11.3B
| $3.34M | ﹤0.01% |
116,951
+83,937
| +254% | +$2.18M |
|
546
Intel
INTC
$413B
| $3.32M | ﹤0.01% |
128,742
-4,626,078
| -97% | -$115M |
|
547
Gyre Therapeutics
GYRE
$629M
| $3.32M | ﹤0.01% |
888
+3
| +0.3% | +$11.1K |
|
|
SUSQ
548
DELISTED
SUSQUEHANNA BANCSHARES INC
SUSQ
| $3.28M | ﹤0.01% |
287,848
-2,861
| -1% | -$32.5K |
|
|
RGLS
549
DELISTED
Regulus Therapeutics
RGLS
| $3.25M | ﹤0.01% |
3,005
+10
| +0.3% | +$11.1K |
|
550
Rockwell Automation
ROK
$51.1B
| $3.23M | ﹤0.01% |
+25,892
| New | +$3.07M |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.